| Vlassis Travias, MD | |
|
59 Ornac, Suite 1, Concord, MA 01742-3317 | |
| (978) 369-7627 | |
| (978) 371-2240 |
| Full Name | Vlassis Travias |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 27 Years |
| Location | 59 Ornac, Concord, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992797195 | NPI | - | NPPES |
| 0158968 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 210620 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emerson Hospital - | W concord, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Ob/gyn Associates Pc | 0941278261 | 5 |
News Archive
If you've ever suffered from a toothache, you know that the pain it causes can be life-disrupting. Alarmingly, there are growing numbers of people across the UK waiting for dental treatment in pain.
Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.
A new analysis of 16 years of publicly accessible health data on 68.5 million Medicare enrollees provides broad evidence that long-term exposure to fine particles in the air - even at levels below current EPA standards - leads to increased mortality rates among the elderly.
Senior citizens who hit the so-called doughnut hole in Medicare's drug benefit will begin getting $250 rebate checks in two weeks, the Obama administration announced Thursday — providing one of the first tangible benefits of the recently enacted healthcare law. The rebates, designed in part to bolster support for the controversial law, are the first steps in a decade-long phase-out of the unpopular gap in Medicare Part D drug coverage.
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
› Verified 1 days ago
| Entity Name | Concord Ob/gyn Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114919313 PECOS PAC ID: 0941278261 Enrollment ID: O20040923000572 |
News Archive
If you've ever suffered from a toothache, you know that the pain it causes can be life-disrupting. Alarmingly, there are growing numbers of people across the UK waiting for dental treatment in pain.
Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.
A new analysis of 16 years of publicly accessible health data on 68.5 million Medicare enrollees provides broad evidence that long-term exposure to fine particles in the air - even at levels below current EPA standards - leads to increased mortality rates among the elderly.
Senior citizens who hit the so-called doughnut hole in Medicare's drug benefit will begin getting $250 rebate checks in two weeks, the Obama administration announced Thursday — providing one of the first tangible benefits of the recently enacted healthcare law. The rebates, designed in part to bolster support for the controversial law, are the first steps in a decade-long phase-out of the unpopular gap in Medicare Part D drug coverage.
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vlassis Travias, MD 59 Ornac, Suite 1, Concord, MA 01742-3317 Ph: (978) 369-7627 | Vlassis Travias, MD 59 Ornac, Suite 1, Concord, MA 01742-3317 Ph: (978) 369-7627 |
News Archive
If you've ever suffered from a toothache, you know that the pain it causes can be life-disrupting. Alarmingly, there are growing numbers of people across the UK waiting for dental treatment in pain.
Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.
A new analysis of 16 years of publicly accessible health data on 68.5 million Medicare enrollees provides broad evidence that long-term exposure to fine particles in the air - even at levels below current EPA standards - leads to increased mortality rates among the elderly.
Senior citizens who hit the so-called doughnut hole in Medicare's drug benefit will begin getting $250 rebate checks in two weeks, the Obama administration announced Thursday — providing one of the first tangible benefits of the recently enacted healthcare law. The rebates, designed in part to bolster support for the controversial law, are the first steps in a decade-long phase-out of the unpopular gap in Medicare Part D drug coverage.
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
› Verified 1 days ago
Avra Jordano-alter, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 59 Ornac, Suite 1, Concord, MA 01742 Phone: 978-369-7627 Fax: 978-371-2240 | |
Christina Therese Thomas, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 59 Ornac, #2suite 1, Concord, MA 01742 Phone: 978-369-7627 Fax: 978-371-2240 | |
Dr. Emily Strehle, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 131 Old Road To 9 Acre Cor, Suite 830, Concord, MA 01742 Phone: 978-371-1396 Fax: 978-371-8277 | |
Dr. Jeffrey Riley, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 133 Old Road To 9 Acre Cor, Emerson Hospital, Concord, MA 01742 Phone: 978-287-3502 | |
Ingrid Anita Balcomb, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 131 Old Road To 9 Acre Cor, Suite 830, Concord, MA 01742 Phone: 978-371-1396 Fax: 978-371-8277 | |
Richard D. Rubin, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 59 Ornac, Suite 1, Concord, MA 01742 Phone: 978-369-7627 Fax: 978-371-2240 | |
Dr. Jonathan Emery Grogins, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 131 Old Road To 9 Acre Cor, Suite 830, Concord, MA 01742 Phone: 978-371-1396 Fax: 978-371-8277 |